Research Article Role of Locoregional Surgery in De Novo Metastatic Breast Cancer
by Al-Uwaisi IA1, Al-Hattali SS2, Al-Aghbari SA3*
1General surgery resident, Oman Medical Specialty Board, Oman.
2Breast oncoplastic surgeon, Nizwa Hospital-Oman.
3Breast Oncology Surgeon, Sultan Qaboos Comprehensive Cancer care and Research Center, Oman.
*Corresponding author: Al-Aghbari SA, Breast Oncology Surgeon, Sultan Qaboos Comprehensive Cancer care and Research Center, Oman.
Received Date: 19 April, 2024
Accepted Date: 29 April, 2024
Published Date: 02 May, 2024
Citation: Al-Uwaisi IA, Al-Hattali SS, Al-Aghbari SA (2024) Role of Locoregional Surgery in De Novo Metastatic Breast Cancer. J Oncol Res Ther 9: 10213. https://doi.org/10.29011/2574-710X.10213.
Abstract
Mini Abstract:
This Retrospective study investigated the impact of locoregional surgical resection of de novo primary breast cancer on survival outcome. The findings in this study suggests that surgery has the potential to extent survival in such patients group. Superior overall survival rates were more favorable when surgery was combined with systemic therapy in patients with low metastatic burden. Further prospective studies are required for further validation of results.
Structured Abstract:
Objectives: The study aims to assess the impact of locoregional breast cancer resection in patients with de novo metastatic breast cancer on overall survival, Progression-Free survival and Time-To-progression.
Introduction: Denovo metastatic breast cancer (MBC) presents a unique challenge to tackle. While traditional treatment approaches focus on systemic therapy, recent recommendations have suggested surgical resection in selected cases to improve the quality of life. However, the role of surgery in managing such patients remains controversial with multiple conflicting evidence from various studies. This retrospective study aimed to assess the impact of surgical resection of the primary breast tumor in De Novo MBC on Overall survival (OS), Progression-Free survival (PFS), and Time-To-Progression (TTP). Additionally, This study has also aimed to identify patients' characteristics that could potentially highly benefit from surgical intervention.
Methods: This study included all de novo MBC cases diagnosed at Sultan Qaboos University Hospital in Oman during the period spanning from 2014 and 2018. The Data were obtained from the electronic medical records in the hospital. The Patient cohort was stratified into two groups: Patients that underwent locoregional resection of the primary breast mass and the second group included patients who exclusively received a systemic therapy modality. Patients’ characteristics were subcategorized and analyzed. Various statistical tools were used to assess the desired outcomes.
Results: Of the 84 patients, 32 underwent locoregional resection while 47 patients received systemic therapy without surgical intervention. Surgical resection has demonstrated a superior impact on prolonging the overall survival of the patient when compared to non-surgical group (50 months vs. 36 months respectively, P=0.004). Surgery appeared to have a better OS when combined with chemotherapy and/or radiotherapy and in patients with low metastatic burden. However, surgery did not have any favorable outcome over systemic therapy alone in prolonging PFS and TTP.
Discussion: This study highlights the impact of surgical intervention in potentially extending the survival of patients with de novo MBC in certain favorable conditions. Nevertheless, it also highlights the need for further extensive prospective studies to validate the current findings.
Conclusion: Surgical Resection in patients with de novo MBC may offer a potential survival benefit most noticeably when combined with chemotherapy and/or radiotherapy in patients with low metastatic burden.
© by the Authors & Gavin Publishers. This is an Open Access Journal Article Published Under Attribution-Share Alike CC BY-SA: Creative Commons Attribution-Share Alike 4.0 International License. Read More About Open Access Policy.